Abstract Body

Background

Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) regimens are widely used and linked to weight gain in some patients, potentially contributing to liver steatosis in people living with HIV (PWH). We assessed predictors of liver steatosis progression over 24 months in PWH from Low-and Middle-Income Countries (LMICs).

Methods

The Sentinel Research Network (SRN)-IeDEA is a multi-regional cohort of PWH ≥40 years, on ART for ≥6 months at enrollment. Participants from Brazil, Côte d’Ivoire, Rwanda, Togo and Zimbabwe with Controlled Attenuation Parameter (CAP) measured at baseline and at month 24 by transient elastography were included. Those with viral hepatitis co-infection or hazardous alcohol intake were excluded. Liver steatosis progression was defined as the development of steatosis (≥S1, CAP ≥248 dB/m) or transition to a higher grade (moderate, CAP ≥268 dB/m; severe, ≥280 dB/m) for those with a lower stage at baseline. Generalized linear mixed regression models assessed the association between INSTI exposure and liver steatosis progression. Confounding variables such as age, sex, BMI, and Type 2 diabetes (T2DM) were adjusted based on literature and directed acyclic graphs for optimal model adjustment. INSTI exposure and confounding factors were included as fixed effects, with participating country modeled as a random effect.

Results

A total of 883 participants (63% female, median age 50 years, IQR: 45–56) were included. At baseline, 56% had a BMI ≥25 kg/m², 11% had T2DM, 94% had HIV RNA <1,000 copies/mL, and 51% were on INSTI-based ART, with 84% for <2 years. Baseline liver steatosis prevalence ranged from 15% (95% CI, 10–21) in Togo to 49% (95% CI, 37–62) in Brazil. Over 2 years of follow-up, the incidence of progression was 10.2 (95% CI, 8.6–11.7) per 100 person-years. No association was found between INSTI exposure and liver steatosis progression (Table), while a positive association was noted with T2DM (aOR 1.87, 1.08-3.21) and a BMI ≥25 kg/m² (aOR 4.54, 2.94 –7.02) at baseline.

Conclusions

INSTI exposure was not associated with liver steatosis progression over 24 months. Preexisting metabolic disorders, including T2DM and overweight/obesity, were predictors of liver steatosis progression, emphasizing the need for targeted prevention strategies. While INSTIs can enhance health outcomes for many PWH, long-term monitoring is crucial, particulary for those at risk for metabolic disorders.

Table or Figure